New drug DNTH103 aims to tame muscle weakness in myasthenia gravis
Disease control
Ongoing
This Phase 2 study tests a drug called DNTH103 (claseprubart) in 65 adults with generalized myasthenia gravis, a condition that causes muscle weakness. Participants receive either the drug or a placebo, first through an IV and then as injections under the skin every two weeks for…
Phase: PHASE2 • Sponsor: Dianthus Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC